| Biomarker ID | 260 |
| PMID | 18347174 |
| Year | 2008 |
| Biomarker | RRM2 |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in Aggressive Prostate Cancer |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include:-Fluoropyrimidine activity,Nucleotide di- and triphosphate biosynthesis and interconversion,Glutathione metabolism,E2F transcription factor network,E2F-mediated regulation of DNA replication |
| Experiment | Non Aggressive Vs Aggressive prostate cancer phenotype |
| Type of Biomarker | Prognostic |
| Cohort | 175 patients were classified as cases (n=86) (systemaic progression in 5 years) and controls (n=87) (no systematic progression in 7 years) on the basis of their gleason score. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.0001 |
| Method Used | RT-PCR |
| Clinical | No |
| Remarks | data from Gleason Pattern (GP) GP4, GP5, and Metastatic samples were named as group 1, represented aggressive disease and GP3 samples named as group 2 represented the nonaggressive disease |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | RRM2 |